Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan

ABSTRACT

The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.

FIELD OF THE INVENTION

The present invention relates to crystalline forms of the mono-sodiumsalt of D-isoglutamyl-D-tryptophan, processes for their preparation,pharmaceutical preparations comprising them, and their use in thetreatment of various conditions and diseases. In particular, the presentinvention relates to crystal modification 1 (polymorphic form F),crystal modification 2 (polymorphic form I), and crystal modification 3(polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

BACKGROUND OF THE INVENTION

The compound D-isoglutamyl-D-tryptophan (also known asH-D-γ-Glu-D-Trp-OH or H-D-iGlu-D-Trp-OH or iDD or D-(iEW) ortimodepressin or thymodepressin) is a synthetic hemoregulatory dipeptidehaving the following chemical structure:

Thymodepressin is the free diacid and has the Chemical Abstracts Service(CAS) Registry Number® 186087-26-3. It is an immunosuppressant andselectively inhibits proliferation of bone marrow cells. It is effectivein the suppression of the immune system during the transplantation ofthe bone marrow, organs and tissues (Semina, O. V et al. (2001) Bulletinof Experimental Biology and Medicine, 131(5), 493-495); the protectionof the bone marrow cells and the immune system against the damagingeffects of chemotherapy and radiation (U.S. Pat. Nos. 5,736,519,6,103,699 and 6,410,515); and the treatment of autoimmune diseases, suchas psoriasis and atopic dermatitis (Sapuntsova, S. G., et al. (May2002), Bulletin of Experimental Biology and Medicine, 133(5), 488-490).

A method for the preparation of thymodepressin was disclosed in example1 of U.S. Pat. Nos. 5,736,519, 6,103,699 and 6,410,515. However, themanufacture of thymodepressin on a large scale cannot be conducted usingthe experimental details of this method since a mixture ofD-glutamyl-D-tryptophan and D-isoglutamyl-D-tryptophan is produced whichmust be separated and purified by ion exchange chromatography resultingin a very low yield (12.25%) of thymodepressin.

U.S. Pat. Nos. 5,736,519, 6,103,699 and 6,410,515 teach that thepeptides disclosed therein may be converted into acid addition salts byreacting with inorganic acids including hydrochloric acid, sulphuricacid, hydrobromic acid, phosphoric acid, etc., or organic acidsincluding formic acid, acetic acid, propionic acid, glycolic acid,lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid,tartaric acid, citric acid, benzoic acid, salicylic acid,benzenesulphonic acid, and toluenesulphonic acids. However, neither thebase addition salts of thymodepressin nor methods for the preparation ofsuch salts are disclosed in these patents.

Thymodepressin is not bioavailable as an oral drug in traditional tabletor capsule form. It is currently being sold in Russia as the di-sodiumsalt in liquid formulation for injection and intranasal administrationfor the treatment of psoriasis, atopic dermatitis and rheumatoidarthritis. The solid form of the di-sodium salt ofD-isoglutamyl-D-tryptophan is an amorphous powder which is hygroscopicand very difficult to handle. The di-sodium salt ofD-isoglutamyl-D-tryptophan has the molecular formula C₁₆H₁₇N₃Na₂O₅ andthe following chemical structure:

The di-sodium salt of D-isoglutamyl-D-tryptophan is not identified bythe CAS Registry System, is not listed in the CAS REGISTR^(SM) File anddoes not have a CAS Registry Number® associated with it. Theidentification and structural confirmation of the di-sodium salt ofD-isoglutamyl-D-tryptophan has been determined by infrared (IR)spectroscopy (Kashirin, D. M., et al. (2000), Pharmaceutical ChemistryJournal, 34(11), 619-622). However, although the di-sodium salt ofD-isoglutamyl-D-tryptophan is known, its preparation, isolation andfurther characterization has not been disclosed.

Through investigations in our laboratory, we have determined that thefreeze-dried di-sodium salt of D-isoglutamyl-D-tryptophan is extremelyhygroscopic; turning into a gel in a matter of minutes in air, and thuscannot easily be handled. A powdery or amorphous form of a compound,intended for pharmaceutical use may give rise to manufacturing problemsdue to bulk density issues, hygroscopicity and variable water contentthat cannot be corrected by vacuum drying. D-isoglutamyl-D-tryptophan isa dipeptide and the drying of an amorphous form at elevated temperature,for example, 80-100° C. under vacuum is not recommended. Thus, there areserious difficulties experienced during the purification of thedi-sodium salt of D-isoglutamyl-D-tryptophan and obtaining the puredi-sodium salt on a manufacturing scale. Further, as discussed above,there is no published procedure for its preparation.

The mono-sodium salt of D-isoglutamyl-D-tryptophan is identified by theCAS Registry System and is listed in the CAS REGISTRY^(SM) File with aCAS Registry Number® of 863988-88-9 and has the following chemicalstructure:

However, there are no references citing the mono-sodium salt ofD-isoglutamyl-D-tryptophan and thus no publication of its identity, itsphysical and/or chemical properties, its characterization in the solidstate or a procedure for its preparation and isolation. Therefore, thereis no supporting evidence for the existence of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

Freeze-dried powders of mono-sodium and di-sodium salts of peptide drugsmay not have controllable powder bulk density ranges for formulation andmay require significant investment in freeze-dried dispersiontechnology.

Therefore, there is a need to develop pharmaceutically acceptable saltsof D-isoglutamyl-D-tryptophan which are crystalline. Such crystallinesalts can generally be purified more easily than an amorphous form andmay possess other advantageous properties, for example in relation totheir particular crystalline form and/or their solubilitycharacteristics and/or their lack of hygroscopicity and/or theirstability characteristics, including their thermal stability propertiesand/or their ability to undergo oxidative degradation.

SUMMARY OF THE INVENTION

We have previously invented a process for the manufacture ofD-isoglutamyl-D-tryptophan and a crystalline polymorph, a novel stablemono-ammonium salt and a process for the manufacturing of themono-ammonium salt. This matter was the subject of Canadian PatentApplication No. 2,569,204, filed on Nov. 28, 2006, and is incorporatedherein by reference. We have also previously invented the calcium,magnesium, potassium, and lithium salts of D-isoglutamyl-D-tryptophanand processes for their manufacture. This matter was the subject ofCanadian Patent Application No. 2,571,645, filed on Dec. 19, 2006, andis incorporated herein by reference.

For the production of pharmaceutical dipeptide preparations, it is oftenadvantageous to employ the carboxylic acid group in the form of aspecific sodium salt which has, for example, a more favorablesolubility, a more favorable absorption behavior, a more favorablestability, a favorable solubility pH, or generally a more favorableproperty profile.

We have determined that D-isoglutamyl-D-tryptophan can form salts withsodium hydroxide, for example a mono-sodium salt, wherein a hydrogenatom from the carboxylic acid is replaced by a sodium ion which can beformally represented by formula III or a di-sodium salt, wherein twohydrogen atoms are replaced by two sodium salts which can be formallyrepresented by formula II.

We have conducted speciation research and concluded the graphical plotsas shown in FIG. 1. We have determined that an advantageous salt for usein pharmaceutical preparations is the mono-sodium salt of theD-isoglutamyl-D-tryptophan, which can be formally represented by formulaIII, which is the predominant pharmaceutical salt at neutral pH. Thistakes advantage of the fact that the amino acid is a zwitterion. We havedetermined that the mono-sodium salt as shown in formula III is the mostpreferred salt in pharmaceutical preparations. The di-sodium salt offormula II is the predominant species at a pH of about 12 or above. Asolution of di-sodium salt in water will have a pH of about 12 andtherefore it is unsuitable for use in a liquid formulation. Adjustmentof a solution of the di-sodium salt back to a pH of about 7 to about7.4, in fact produces the mono-sodium salt as the predominant species insolution.

Thus, an object of the present invention is to provide the mono-sodiumsalt of D-isoglutamyl-D-tryptophan in a form suitable for pharmaceuticaluse and made by a process suitable for being carried out on a largeindustrial scale.

A stable crystalline mono-sodium salt can be used in pharmaceuticalpreparations that are tailored with respect to their composition and theroute of administration provide the medicinal effects desired in thespecific case.

It has now been determined by us that the mono-sodium salt of theD-isoglutamyl-D-tryptophan can be prepared in a solid crystalline formsuitable for pharmaceutical use by reaction of theD-isoglutamyl-D-tryptophan with basic sodium compounds, for examplesodium hydroxide. The use of sodium hydride, sodium carbonate, sodiumbicarbonate, sodium C₁-C₄ alkoxides are considered obvious chemicalequivalents to sodium hydroxide. Surprisingly, it turned out here thatthe solid crystalline mono-sodium salt of the D-isoglutamyl-D-tryptophancan occur in a number of different crystal modifications, i.e., inpolymorphic forms, which can be prepared specifically by adjustment ofthe reaction conditions and/or of the crystallization conditions andwhich differ in their physicochemical properties. Thus, these crystalmodifications may differ, for example, in their solubility, rate ofdissolution, or behavior during pharmaceutical processing, and allow theproduction of pharmaceutical preparations having different propertyprofiles starting from a single parent compound.

In accordance with one aspect of the present invention, there isprovided the mono-sodium salt of D-isoglutamyl-D-tryptophan incrystalline form.

In another embodiment of the present invention, the crystalline form ofthe mono-sodium salt of D-isoglutamyl-D-tryptophan produce distinctpeaks in a X-ray diffraction measurement having a half-value width below2° measured at the reflection angle 2 theta using CuK_(α) radiation.

In another embodiment of the present invention, the crystalline form ofthe mono-sodium salt of D-isoglutamyl-D-tryptophan is crystalmodification 1 (polymorphic form F).

In another embodiment of the present invention, crystal modification 1(polymorphic form F) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan has the XRPD pattern as provided in FIG. 2.

In another embodiment of the present invention, crystal modification 1(polymorphic form F) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan is characterized by peaks in the XRPD patternhaving the following 26 values: 9.23±0.20, 9.91±0.20, 12.41±0.20,13.76±0.20, 14.87±0.20, 15.75±0.20, 17.88±0.20, 18.78±0.20, 19.57±0.20,19.84±0.20, 20.31±0.20, 21.32±0.20, 21.55±0.20, 22.95±0.20, 23.45±0.20,24.34±0.20, 24.96±0.20, 27.49±0.20, 27.94±0.20, 29.27±0.20, 30.07±0.20,30.43±0.20, 31.29±0.20, 32.25±0.20, 34.07±0.20, 34.94±0.20, 35.53±0.20,36.08±0.20, 37.21±0.20, 38.17±0.20, 39.19±0.20, and 9.23±0.20.

In another embodiment of the present invention, crystal modification 1(polymorphic form F) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan is characterized by peaks in the XRPD patternhaving the following 26 values: 9.23±0.10, 9.91±0.10, 12.41±0.10,13.76±0.10, 14.87±0.10, 15.75±0.10, 17.88±0.10, 18.78±0.10, 19.57±0.10,19.84±0.10, 20.31±0.10, 21.32±0.10, 21.55±0.10, 22.95±0.10, 23.45±0.10,24.34±0.10, 24.96±0.10, 27.49±0.10, 27.94±0.10, 29.27±0.10, 30.07±0.10,30.43±0.10, 31.29±0.10, 32.25±0.10, 34.07±0.10, 34.94±0.10, 35.53±0.10,36.08±0.10, 37.21±0.10, 38.17±0.10, 39.19±0.10, and 9.23±0.10.

In another embodiment of the present invention, crystal modification 1(polymorphic form F) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan is characterized by an XRPD pattern expressedin terms of inter-planar distances d, Bragg's angle 2 theta, andrelative intensity (expressed as a percentage with respect to the mostintense ray) as follows:

2 Theta D-spacing Relative Intensity (°) (Angstrom) (%) 9.23 9.573 29.91 8.917 41.3 12.41 7.126 37.6 13.76 6.43 0.8 14.87 5.954 35.8 15.755.622 7.6 17.88 4.957 5.5 18.78 4.721 58.9 19.57 4.532 30.9 19.84 4.47128.1 20.31 4.368 2.9 21.32 4.165 53.5 21.55 4.12 30.3 22.95 3.873 67.423.45 3.79 24.5 24.34 3.654 19.4 24.96 3.565 85.2 27.49 3.242 100 27.943.19 23.3 29.27 3.049 19.1 30.07 2.97 27.2 30.43 2.935 15.2 31.29 2.85639.9 32.25 2.774 13 34.07 2.629 19.3 34.94 2.566 7.8 35.53 2.525 5 36.082.487 8.4 37.21 2.414 15.5 38.17 2.356 9.1 39.19 2.297 3.1

In another embodiment of the present invention, the crystalline form ofthe mono-sodium salt of D-isoglutamyl-D-tryptophan is crystalmodification 2 (polymorphic form I).

In another embodiment of the present invention, crystal modification 2(polymorphic form I) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan has the XRPD pattern provided in FIG. 3.

In another embodiment of the present invention, crystal modification 2(polymorphic form I) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan is characterized by peaks in the XRPD patternhaving the following 26 values: 9.65±0.20, 10.41±0.20, 11.2±0.20,11.71±0.20, 13.45±0.20, 13.93±0.20, 14.44±0.20, 15.61±0.20, 17.01±0.20,18.18±0.20, 18.65±0.20, 20.02±0.20, 20.85±0.20, 21.39±0.20, 21.73±0.20,22.52±0.20, 23.27±0.20, 24.3±0.20, 25.84±0.20, 26.82±0.20, 28.49±0.20,30.18±0.20, 30.76±0.20, 31.49±0.20, 33.03±0.20, 34.55±0.20, 34.97±0.20,35.74±0.20, 37.25±0.20, 37.71±0.20, and 38.79±0.20.

In another embodiment of the present invention, crystal modification 2(polymorphic form I) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan is characterized by peaks in the XRPD patternhaving the following 26 values: 9.65±0.10, 10.41±0.10, 11.2±0.10,11.71±0.10, 13.45±0.10, 13.93±0.10, 14.44±0.10, 15.61±0.10, 17.01±0.10,18.18±0.10, 18.65±0.10, 20.02±0.10, 20.85±0.10, 21.39±0.10, 21.73±0.10,22.52±0.10, 23.27±0.10, 24.3±0.10, 25.84±0.10, 26.82±0.10, 28.49±0.10,30.18±0.10, 30.76±0.10, 31.49±0.10, 33.03±0.10, 34.55±0.10, 34.97±0.10,35.74±0.10, 37.25±0.10, 37.71±0.10, and 38.79±0.10.

In another embodiment of the present invention, crystal modification 2(polymorphic form I) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan is characterized by an XRPD pattern expressedin terms of inter-planar distances d, Bragg's angle 2 theta, andrelative intensity (expressed as a percentage with respect to the mostintense ray) as follows:

2-Theta D-spacing Relative Intensity (°) (Angstrom) (%) 9.65 9.161 5.310.41 8.492 23.7 11.2 7.897 40.4 11.71 7.549 4.5 13.45 6.58 90.2 13.936.351 15.9 14.44 6.128 3.7 15.61 5.672 32.4 17.01 5.207 9.9 18.18 4.87611.7 18.65 4.755 47.8 20.02 4.432 59.2 20.85 4.257 35.9 21.39 4.15 24.121.73 4.086 27.3 22.52 3.945 100 23.27 3.819 13.7 24.3 3.66 32.4 25.843.445 69.5 26.82 3.322 82.5 28.49 3.13 30.1 30.18 2.959 58.8 30.76 2.90486.9 31.49 2.839 35.3 33.03 2.71 8.7 34.55 2.594 17.8 34.97 2.564 43.435.74 2.51 8.5 37.25 2.412 28.1 37.71 2.383 28.5 38.79 2.319 16.9

In another embodiment of the present invention, the crystalline form ofthe mono-sodium salt of D-isoglutamyl-D-tryptophan is crystalmodification 3 (polymorphic form X).

In another embodiment of the present invention, crystal modification 3(polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan has the XRPD pattern provided in FIG. 4.

In another embodiment of the present invention, crystal modification 3(polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan is characterized by peaks in the XRPD patternhaving the following 26 values: 9.187±0.200, 11.058±0.200, 11.713±0.200,12.239±0.200, 13.785±0.200, 14.806±0.200, 15.763±0.200, 17.126±0.200,17.693±0.200, 18.268±0.200, 18.562±0.200, 19.261±0.200, 20.033±0.200,20.63±0.200, 21.006±0.200, 21.778±0.200, 22.268±0.200, 23.054±0.200,23.361±0.200, 23.851±0.200, 24.626±0.200, 24.981±0.200, 25.507±0.200,26.257±0.200, 26.963±0.200, 27.329±0.200, 27.807±0.200, 28.243±0.200,28.975±0.200, 29.264±0.200, 29.687±0.200, 30.409±0.200, 30.798±0.200,31.193±0.200, 31.724±0.200, 32.505±0.200, 32.985±0.200, 33.645±0.200,34.249±0.200, 34.587±0.200, 35.048±0.200, 35.41±0.200, 35.933±0.200,36.833±0.200, 37.276±0.200, 37.937±0.200, 38.467±0.200, and 39±0.200.

In another embodiment of the present invention, crystal modification 3(polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan is characterized by peaks in the XRPD patternhaving the following 26 values: 9.187±0.100, 11.058±0.100, 11.713±0.100,12.239±0.100, 13.785±0.100, 14.806±0.100, 15.763±0.100, 17.126±0.100,17.693±0.100, 18.268±0.100, 18.562±0.100, 19.261±0.100, 20.033±0.100,20.63±0.100, 21.006±0.100, 21.778±0.100, 22.268±0.100, 23.054±0.100,23.361±0.100, 23.851±0.100, 24.626±0.100, 24.981±0.100, 25.507±0.100,26.257±0.100, 26.963±0.100, 27.329±0.100, 27.807±0.100, 28.243±0.100,28.975±0.100, 29.264±0.100, 29.687±0.100, 30.409±0.100, 30.798±0.100,31.193±0.100, 31.724±0.100, 32.505±0.100, 32.985±0.100, 33.645±0.100,34.249±0.100, 34.587±0.100, 35.048±0.100, 35.41±0.100, 35.933±0.100,36.833±0.100, 37.276±0.100, 37.937±0.100, 38.467±0.100, and 39±0.100.

In another embodiment of the present invention, crystal modification 3(polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan is characterized by an XRPD pattern expressedin terms of inter-planar distances d, Bragg's angle 2 theta, andrelative intensity (expressed as a percentage with respect to the mostintense ray) as follows:

2-Theta D-spacing Relative Intensity (°) (Angstrom) (%) 9.187 9.618 25.411.058 7.995 2.3 11.713 7.549 18.7 12.239 7.226 34.2 13.785 6.419 23.514.806 5.978 13 15.763 5.618 5 17.126 5.173 29.3 17.693 5.009 8.4 18.2684.852 48.2 18.562 4.776 28.2 19.261 4.604 14.3 20.033 4.429 14.5 20.634.302 17.2 21.006 4.226 12 21.778 4.078 2.4 22.268 3.989 100 23.0543.855 6.4 23.361 3.805 7.4 23.851 3.728 1.8 24.626 3.612 14.9 24.9813.562 14.7 25.507 3.489 11.1 26.257 3.391 34.3 26.963 3.304 11.1 27.3293.261 20.6 27.807 3.206 35 28.243 3.157 25.6 28.975 3.079 1.1 29.2643.049 2.3 29.687 3.007 9.5 30.409 2.937 20.9 30.798 2.901 6.1 31.1932.865 6.9 31.724 2.818 24.7 32.505 2.752 8 32.985 2.713 12.1 33.6452.662 26.5 34.249 2.616 15.2 34.587 2.591 8.6 35.048 2.558 4.6 35.412.533 3.3 35.933 2.497 15.3 36.833 2.438 8 37.276 2.41 10.8 37.937 2.3712.7 38.467 2.338 14.7 39 2.308 2.6

In another embodiment of the present invention, the crystalline form ofthe mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture ofcrystal modifications 1 (polymorphic form F) and 2 (polymorphic form I)of the mono-sodium salt of D-isoglutamyl-D-tryptophan.

In another embodiment of the present invention, the crystalline form ofthe mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture of thecrystal modifications 1 (polymorphic form F) and 3 (polymorphic form X)of the mono-sodium salt of D-isoglutamyl-D-tryptophan.

In another embodiment of the present invention, the mixture of thecrystal modifications 1 (polymorphic form F) and 3 (polymorphic form X)of the mono-sodium salt of D-isoglutamyl-D-tryptophan has the XRPDpattern provided in FIG. 9.

In accordance with another aspect of the present invention, there isprovided a pharmaceutical composition comprising any of the crystallineforms of the mono-sodium salt of D-isoglutamyl-D-tryptophan describedabove, together with at least one pharmaceutically acceptable carrier.

In accordance with another aspect of the present invention, there isprovided a process for making a pharmaceutical composition comprisingany of the crystalline forms of the mono-sodium salt ofD-isoglutamyl-D-tryptophan described above, wherein said processcomprises combining any of the crystalline forms of the mono-sodium saltof D-isoglutamyl-D-tryptophan as described above, with at least onepharmaceutically acceptable carrier.

In accordance with another aspect of the present invention, there isprovided a use of any of the crystalline forms of the mono-sodium saltof D-isoglutamyl-D-tryptophan described above, without chromatographicpurification in the manufacture of a pharmaceutical composition.

In accordance with another aspect of the present invention, there isprovided a use of any of the crystalline forms of the mono-sodium saltof D-isoglutamyl-D-tryptophan as an anti-psoriasis agent.

In accordance with another aspect of the present invention, there isprovided a process for the preparation of the mono-sodium salt ofD-isoglutamyl-D-tryptophan in crystalline form, comprising the steps of:

-   -   (a) preparing a solution of D-isoglutamyl-D-tryptophan and        sodium hydroxide in water at a pH of about 6.5 to about 7.2;    -   (b) filtering the solution to remove solid particulates;    -   (c) evaporating the water to concentrate the filtrate; and    -   (d) adding isopropanol to precipitate the mono-sodium salt of        D-isoglutamyl-D-tryptophan,        or    -   (e) stirring the solid obtained from process steps (a), (b),        (c), and (d) with ethyl acetate; and    -   (f) filtering the solid,

Or

-   -   steps (a) and (b) as described above, followed by steps:    -   (g) evaporating the filtrate from step (b) to give a solid;    -   (h) adding water to obtain a solution of the mono-sodium salt of        D-isoglutamyl-D-tryptophan; and    -   (i) evaporating the water over a period of more than about 5 hrs        to give the mono-sodium salt of D-isoglutamyl-D-tryptophan in        crystalline form,        or    -   (j) preparing a solution of the mono-sodium salt of        D-isoglutamyl-D-in methanol;    -   (k) filtering the solution to remove solid particulates; and    -   (l) adding isopropanol to precipitate the mono-sodium salt of        D-isoglutamyl-D-tryptophan,        or    -   (m) preparing a solution of the mono-ammonium salt of        D-isoglutamyl-D-tryptophan and sodium hydroxide in water,    -   followed by steps (b), (c) and (d) as described above.

In an embodiment of the present invention, wherein the process comprisessteps (a), (b), (c) and (d), the stirring time in step (d) is from about1.5 to about 16 hrs.

In another embodiment of the present invention, wherein the processcomprises steps (a), (b), (c) and (d), the stirring time in step (d) isabout 1 hr.

In another embodiment of the present invention, wherein the processcomprises steps (a), (b), (c), (d), (e) and (f), the stirring time instep (d) is about 1 hr and the stirring time in ethyl acetate in step(f) is about 2.5 hrs.

In another embodiment of the present invention, wherein the processcomprises steps (a), (b), (g), (h) and (i), from about 18 to about 22 mlof water is added per gm of the mono-sodium salt ofD-isoglutamyl-D-tryptophan in step (h) and the evaporation time in step(i) is from about 5 to about 6 hours and the temperature of evaporationis from about 30 to about 35° C.

In another embodiment of the present invention, wherein the processcomprises steps (j), (k), and (l), the ratio of the mono-sodium salt ofD-isoglutamyl-D-tryptophan is 1 gm per about 11 to about 13 ml methanolin step (j) and the ratio of isopropanol to methanol in step (l) is fromabout 0.4 to 0.6 ml to about 1 ml.

In another embodiment of the present invention, wherein the processcomprises steps (m), (b), (c) and (d), the stirring time in step (d) isfrom about 12 to about 16 hours.

Other and further advantages and features of the present invention willbe apparent to those skilled in the art from the following g detaileddescription thereof taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

In the accompanying drawings:

FIG. 1 is a speciation plot of the dipeptide H-D-iGlu-D-Trp-OH and itssalt calculated using experimentally determined pKas of the acid andamine groups.

FIG. 2 is a characteristic XRPD pattern of crystal modification 1(polymorphic form F) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

FIG. 3 is a characteristic XRPD pattern of crystal modification 2(polymorphic form I) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

FIG. 4 is a characteristic XRPD pattern of crystal modification 3(polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

FIG. 5 is a characteristic infrared (IR) absorption spectrum of crystalmodification 1 (polymorphic form F) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

FIG. 6 is a characteristic infrared (IR) absorption spectrum of crystalmodification 2 (polymorphic form I) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

FIG. 7 is a characteristic infrared (IR) absorption spectrum of crystalmodification 3 (polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

FIG. 8 shows the comparison of the XRPD pattern of crystal modification1 (polymorphic form F), crystal modification 2 (polymorphic form I), andcrystal modification 3 (polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

FIG. 9 is a characteristic XRPD pattern of a mixture of the crystalmodification 1 (polymorphoric form F) and crystal modification 3(polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

DETAIL DESCRIPTION OF INVENTION

As used herein, D-isoglutamyl-D-tryptophan is the dipeptide

The chemistry of amino acids or simple dipeptides is complicated by thefact that the —NH₂ group is a base and the —CO₂H group is an acid. Inaqueous solution, an H⁺ ion is therefore transferred from one end of themolecule to the other to form zwitterions.

Zwitterions are simultaneously electrically charged and electricallyneutral. They contain positive and negative charges, but the net chargeon the molecule is zero. Although the basis for salt formation is notentirely bound by theory, the iGlu amino acid unit of H-D-iGlu-D-Trp-OHexists as a zwitterion, and therefore only one —CO₂H group is left thatis available for the formation of a salt when only one equivalent ofmonovalent sodium hydroxide is used to adjust the pH to neutralconditions. When H-D-iGlu-D-Trp-OH mono-sodium salt of formula III isdrawn in the format shown above, only one CO₂H group can accommodate onemono-sodium metal to give the salt of formula III. In the compound offormula (III), a sodium cation displaces one hydrogen atom, on thecarboxylic acid portion of the compound of formula (I).

FIG. 1 is a speciation plot of the dipeptide H-D-iGlu-D-Trp-OH and itssalt calculated with the software Hyperquad Simulation & Speciationusing experimentally determined pKas of the acid and amine groups.LH₂═H-D-iGlu-D-Trp-OH in diacid form represented by a compound offormula I, LH=mono carboxylic acid salt such as the mono-sodium saltrepresented by a compound of formula III, L=dicarboxylic acid salt suchas the di-sodium salt represented by a compound of formula II, LH₃=acidaddition salt of H-D-iGlu-D-Trp-OH such as the mono hydrochloride saltof a compound of formula I wherein the NH₂ is protonated. The X axisprovides the pH of the solution. The Y axis reports the molar fractionof the species present at a particular pH. Note: % formation relative toL is the default terminology of the software. The concentration of 0.5Mis used to reflect the equivalency of 1 gm of thymodepressin in 6 mlwater during isolation purposes. This figure shows that about 100% ofthe thymodepressin is in the mono-sodium salt form in water at a pH ofabout 7.0 to about 7.4.

The present invention is directed to the novel mono-sodium salt ofD-isoglutamyl-D-tryptophan of formula (III), novel crystalline forms ofthe mono-sodium salt of D-isoglutamyl-D-tryptophan, including novelcrystal modification 1 (polymorphic form F), novel crystal modification2 (polymorphic form I), and novel crystal modification 3 (polymorphicform X).

The present invention is also directed to a process for the preparationof the novel crystal modification 1 (polymorphic form F), the novelcrystal modification 2 (polymorphic form I), the novel crystalmodification 3 (polymorphic form X), and a mixture of the novel crystalmodifications 1 and 3 of the mono-sodium salt ofD-isoglutamyl-D-tryptophan, wherein the process comprises the steps of:

-   -   (a) preparing a solution of D-isoglutamyl-D-tryptophan and        sodium hydroxide in water at a pH from about 6.5 to about 7.0;    -   (b) filtering the solution to remove solid particulates;    -   (c) evaporating the water to concentrate the filtrate; and    -   (d) adding isopropanol to precipitate the mono-sodium salt of        D-isoglutamyl-D-tryptophan,        or    -   steps (a), (b), (c), and (d) as described above, followed by the        steps of:    -   (e) stirring the solid obtained from step (d) with ethyl        acetate; and    -   (f) filtering of the solid,        or    -   steps (a) and (b) as described above, followed by the steps of:    -   (g) evaporating the filtrate from step (b) to give a solid;    -   (h) adding water to obtain a solution of the mono-sodium salt of        D-isoglutamyl-D-tryptophan; and    -   (i) evaporating the water over a period of more than about 5 hrs        to give the mono-sodium salt of D-isoglutamyl-D-tryptophan in        crystalline form,        or    -   (j) preparing a solution of the mono-sodium salt of        D-isoglutamyl-D-in methanol;    -   (k) filtering the solution to remove solid particulates; and    -   (l) adding isopropanol to precipitate the mono-sodium salt of        D-isoglutamyl-D-tryptophan,        or    -   (m) preparing a solution of the mono-ammonium salt of        D-isoglutamyl-D-tryptophan and sodium hydroxide in water,    -   followed by steps (b), (c) and (d) as described above.

Preferably, the process comprising steps (a), (b), (c) and (d) asdescribed above is used to prepare the crystal modification 1(polymorphic form F) and the crystal modification 2 (polymorphic form I)of the mono-sodium salt of D-isoglutamyl-D-tryptophan. The processcomprises the steps of:

-   -   (a) preparing a solution of D-isoglutamyl-D-tryptophan and        sodium hydroxide in water;    -   (b) filtering the solution to remove solid particulates;    -   (c) evaporating the water to concentrate the filtrate; and    -   (d) adding isopropanol to precipitate the mono-sodium salt of        D-isoglutamyl-D-tryptophan.

Depending on the volume ratio of isopropanol to the solution ofmono-sodium salt of D-isoglutamyl-D-tryptophan and its concentration andthe stirring time, pure crystal modification 1 or pure crystalmodification 2 can be obtained by this process. Based on speciation plotcalculations as provided in FIG. 1, the pH of the solution from step (a)should be at a pH of about 6.5 to about 7.2, preferably at a pH of about7.0, before proceeding to step (b).

A solution of D-isoglutamyl-D-tryptophan and sodium hydroxide in wateris prepared by adding solid D-isoglutamyl-D-tryptophan to sodiumhydroxide solution. D-isoglutamyl-D-tryptophan has limited solubility inwater (<20 mg per ml in water), but the sodium salt is extremely solublein water. Sodium hydroxide is chosen based on the convenience inobtaining sodium hydroxide solution, however other sodium bases such assodium hydride, sodium carbonate, sodium bicarbonate can be used. Thesechemicals are obvious chemical equivalents to sodium hydroxide for step(a) of the process. In step (b), the solution is filtered to remove anyparticulates prior to proceeding to step (c).

In the process for the preparation of crystal modification 1, thefiltrate from step (b) is then concentrated to remove water to reach anestimated concentration of about 1.3 to about 3 mmol/ml of the solute insolution in step (c). The solute is the mono-sodium salt ofD-isoglutamyl-D-tryptophan. An anti-solvent is used to precipitate themono-sodium salt. As used herein, an anti-solvent is a solvent that cancause the precipitation of a solute in solution. Examples of ananti-solvent for use in the present invention are isopropanol and C₁-C₄alkanol. In a preferred embodiment, isopropanol is used as ananti-solvent to precipitate the mono-sodium salt. In step (d), about 30to about 40 ml of isopropanol per ml of the sodium salt ofisoglutamyl-D-tryptophan in water is added to initiate the precipitationof the crystal modification 1 of the mono-sodium salt ofD-isoglutamyl-D-tryptophan. The stirring time is from about 1.5 to about16 hrs, preferably from about 12 to about 16 hrs. The solid is isolatedby filtration and dried under high vacuum in a vacuum oven. Thepreferred temperature of drying is from about 40 to about 45° C., andthe preferred vacuum setting is below about 8 mm Hg. Still preferred,the applied vacuum is below about 5 mm Hg.

In the process for the preparation of crystal modification 2, thefiltrate from step (b) is then concentrated to remove water in step (c)to reach an estimated concentration of about 3 to about 18 mmol/ml ofthe solute in solution. The solute is the mono-sodium salt ofD-isoglutamyl-D-tryptophan. Isopropanol is used as an anti-solvent toprecipitate the mono-sodium salt. About 40 ml of isopropanol per ml ofthe mono-sodium salt of D-isoglutamyl-D-tryptophan in water is added toprecipitate the crystal modification 2 of the mono-sodium salt ofD-isoglutamyl-D-tryptophan. The stirring time is about 1 hour. The solidis isolated by filtration and dried under high vacuum in a vacuum oven.The preferred temperature of drying is from about 40 to about 45° C.,and the preferred vacuum setting is below about 8 mm Hg. Stillpreferred, the applied vacuum is below about 5 mm Hg.

Although not bound by theory, we have determined that in the isopropanolprecipitation reaction in step (d), the stirring time plays an importantrole in determining the crystal modification 1 or 2 as the product ofthe reaction. A short stirring time of about one hour or less than aboutone hour results in crystal modification 2 (polymorphic form I), while along stirring time of up to about 16 hours resulted in the crystalmodification 1 (polymorphic form F). The outcome of the crystalmodification also depends on the concentration of the mono-sodium saltin solution and the amount of isopropanol added as an anti-solvent.Details of the experimental conditions can be found in Examples 1 and 2described below.

We have also found that when a solution of mono-sodium salt of formulaIII in water is precipitated with isopropanol at about 3 mmol/mlconcentration, a mixture of crystal modification 1 (polymorphic form F)and crystal modification 3 (polymorphic form X) can be obtained. Whenthis mixture is stirred with ethyl acetate and then filtered, themajority of the crystalline form is the crystal modification 1 and theexperimental information is provided in Example 4B described in moredetail below.

Therefore, preferably, a process for producing the crystal modification1 (polymorphic form F) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan comprises the following steps:

-   -   (a) preparing a solution of D-isoglutamyl-D-tryptophan and        sodium hydroxide in water at a pH of about 6.5 to about 7.0;    -   (b) filtering the solution to remove solid particulates;    -   (c) evaporating the water to concentrate the filtrate;    -   (d) adding isopropanol to precipitate the mono-sodium salt of        D-isoglutamyl-D-tryptophan;    -   (e) stirring the solid obtained in step (d) with ethyl acetate;        and    -   (f) filtering of the solid.

The presence of crystal modification 3 (polymorphic form X) in a mixturewith crystal modification 1 (polymorphic form F) required furtherresearch which lead to the invention of two processes for thepreparation of crystal modification 3.

Preferably, the process comprising steps (a), (b), (g), (h) and (i) asdescribed above is used to prepare the crystal modification 3(polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan. The process comprises the steps of:

-   -   (a) preparing a solution of D-isoglutamyl-D-tryptophan and        sodium hydroxide in water at a pH of about 6.5 to about 7.2;    -   (b) filtering the solution to remove solid particulates;    -   (g) evaporating the filtrate from step (b) to give a solid;    -   (h) adding water to obtain a solution of the mono-sodium salt of        D-isoglutamyl-D-tryptophan; and    -   (i) evaporating the water over a period of more than about 5 hrs        to give the mono-sodium salt of D-isoglutamyl-D-tryptophan in        crystalline form.

Steps (a) and (b) are carried out as those described above. In step (g),about 18 to about 22 ml of water is added per gm of the mono-sodium saltof D-isoglutamyl-D-tryptophan to prepare the solution. Slow solventevaporation under reduced pressure affords the crystal modification 3(polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan. In step (h), the solvent evaporation isconducted in a round bottom flask using a rotor evaporator under vacuum.The preferred temperature of the external water bath for the solventevaporation is about 30 to about 35° C., the preferred vacuum is about14 to about 20 mm Hg, and the preferred time period of evaporation isabout 5 to about 7 hrs.

Alternatively but also preferably, the process comprising steps (j),(k), and (I) is used to prepare crystal modification 3 (polymorphic formX) of the mono-sodium salt of D-isoglutamyl-D-tryptophan. The processcomprises the steps of:

-   -   (j) preparing a solution of the mono-sodium salt of        D-isoglutamyl-D-tryptophan in methanol;    -   (k) filtering the solution to remove solid particulates; and    -   (l) adding isopropanol to precipitate the mono-sodium salt of        D-isoglutamyl-D-tryptophan.

In step (j), a solution of the mono-sodium salt ofD-isoglutamyl-D-tryptophan in methanol is prepared by dissolving thesolid mono-sodium salt (in any polymorphic form) in methanol. Heating ofthe suspension in methanol is required to facilitate dissolution. Thepreferred concentration of the solute (mono-sodium salt) to methanol is1 gm solute per about 11 to about 13 ml of methanol. The insolubleparticulates are then filtered in step (k). About 0.4 to about 0.6 ml ofisopropanol is added to per ml of the methanol solution from step (l).The insoluble material is isolated by suction filtration, and is thecrystal modification 3 (polymorphic form X) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

In another embodiment of the present invention, the mono-sodium salt ofD-isoglutamyl-D-tryptophan can be prepared by salt exchange reactionbetween the mono-ammonium salt of D-isoglutamyl-D-tryptophan and sodiumhydroxide. The process comprises steps (m), (b), (c) and (d) asdescribed above and as follows:

-   -   (m) preparing a solution of the mono-ammonium salt of        D-isoglutamyl-D-tryptophan and sodium hydroxide in water;    -   (b) filtering the solution to remove solid particulates;    -   (c) evaporating the water to concentrate the filtrate; and    -   (d) adding isopropanol to precipitate the mono-sodium salt of        D-isoglutamyl-D-tryptophan.

In step (m), the mono-ammonium salt of D-isoglutamyl-D-tryptophan andsodium hydroxide is mixed in roughly about 1:1 ratio in water. Thesolution is filtered in step (b). It should be noted that in step (m),ammonium hydroxide is released. Therefore, the pH of the solution ishigher than a pH of about 7.5. No pH adjustment is required. Thefiltrate is concentrated to an estimated concentration of about 0.25 toabout 0.5 gm solute (mono-sodium salt) in per ml of water. In step (d),about 15 to about 30 ml of isopropanol is added to per ml of thesolution from step (c) to precipitate the crystal modification 1(polymorphic form F) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.

As described in Example 4 of the present invention, the mixed polymorphof the mono-sodium salt containing the crystal modifications 1 and 3 canalso be obtained from the reaction of D-isoglutamyl-D-tryptophan withsodium hydroxide by varying the conditions. As part of the presentinvention, we have illustrated the conversion of a mixture of crystalmodifications 1 and 3 to mainly crystal modification 1 in Example 4 bystirring the solid in ethyl acetate.

As generally illustrated above for the preparation of the mono-sodiumsalt of the D-isoglutamyl-D-tryptophan, it can be advantageous whencarrying out this process as well as the other processes described toadditionally add isopropanol to the aqueous solution of the sodium saltfor the isolation of the sodium salt crystalline solid.

Although not bound by theory, a short stirring time, normally about onehour or less, with isopropanol produces the crystal modification 2(polymorphoric form I) of the mono-sodium salt of formula III. A longstirring time, up to about 16 hrs produces the crystal modification 1(polymorphoric form F). In cases when a mixture of the crystalmodification 1 (polymorphoric form F) and the crystal modification 3(polymorphoric form X) are produced, pure crystal modification 1 can beproduced by stirring in ethyl acetate.

When a solution of the mono-sodium salt is prepared in methanol, the useof isopropanol as an anti-solvent affords the crystal modification 3 ofthe present invention.

The pharmacological properties of the crystalline mono-sodium salt ofD-isoglutamyl-D-tryptophan and crystal modifications 1, 2, and 3 andtheir possible uses for the therapy and prophylaxis of disorderscorrespond, if the substances are present in the target organ or in thetarget cell in dissolved form independent of the original form of thesolid, to those described for thymodepressin and its disodium salt,which are described in, among others, U.S. Pat. Nos. 5,736,519,6,103,699 and 6,410,5151 Semina, O. V et al. (2001), Bulletin ofExperimental Biology and Medicine, 131(5), 493-495); and Sapuntsova, S.G., et al. (May 2002), Bulletin of Experimental Biology and Medicine,133(5), 488-490).

The action of crystal modifications 1, 2, and 3 can be investigated, forexample, in the pharmacological models which are described in, amongothers, U.S. Pat. Nos. 5,736,519, 6,103,699 and 6,410,515; Semina, 0. Vet al. (2001), Bulletin of Experimental Biology and Medicine, 131(5),493-495); and Sapuntsova, S. G., et al. (May 2002), Bulletin ofExperimental Biology and Medicine, 133(5), 488-490), which areincorporated herein by reference and the respective contents of whichare part of the present disclosure.

The crystal modifications of the mono-sodium salt ofD-isglutamyl-D-tryptophan according to the present invention can thus beused in animals, preferably in mammals, and in particular in humans aspharmaceuticals on their own, in mixtures with one another, or in theform of pharmaceutical preparations (or pharmaceutical compositions).The present invention therefore also relates to the crystallinemono-sodium salt of the D-isoglutamyl-D-tryptophan and the crystalmodifications of the mono-sodium salt of the D-isoglutamyl-D-tryptophanfor use as pharmaceuticals, their use as anti-psoriasis agents, and inparticular their use as an immunosupressant, and also their use for theproduction of medicaments thereof. The present invention furthermorerelates to pharmaceutical preparations which contain, as activeconstituents, an efficacious dose of the crystalline mono-sodium salt ofthe D-isoglutamyl-D-tryptophan, in particular of the mono-sodium salt ofthe D-isoglutamyl-D-tryptophan in the form of one or more of the crystalmodifications 1, 2, and 3, and at least one pharmaceutically acceptablecarrier, that is one or more vehicles and/or excipients. Thesepharmaceutical preparations contain, for example, the mono-sodium saltof the D-isoglutamyl-D-tryptophan in crystal modification 1 and at leastone pharmaceutically acceptable carrier, or the mono-sodium salt ofD-isoglutamyl-D-tryptophan in crystal modification 2 and at least onepharmaceutically acceptable carrier, or the mono-sodium salt ofD-isoglutamyl-D-tryptophan in crystal modification 3 and at least onepharmaceutically acceptable carrier, or, for example, two of the crystalmodifications according to the present invention such as crystalmodifications 1 and 2, or crystal modifications 1 and 3, or crystalmodifications 2 and 3, in each case together with at least onepharmaceutically acceptable carrier.

Utility and Administration

The di-sodium salt of D-isoglutamyl-D-tryptophan has been used for thetreatment of psoriasis, atopic dermatitis and rheumatoid arthritis.Therefore the mono-sodium salt of D-isoglutamyl-D-tryptophan of thisinvention may be formulated into pharmaceutical compositions foradministration to subjects in a therapeutically active amount and in abiologically compatible form suitable for in vivo administration, i.e. aform of the peptides to be administered in which any toxic effects areoutweighed by the therapeutic effects.

According to the speciation plot as shown in FIG. 1, the dominantspecies at neutral pH is the mono carboxylate form of thymodepressin,that is, the mono-sodium salt of the dipetideD-isoglutamyl-D-tryptophan, if the counterion is sodium. The di-sodiumsalt of D-isoglutamyl-D-tryptophan is extremely hygroscopic and is verydifficult to handle for dispensing purposes. Depending on itsconcentration, the pH of a solution of di-sodium salt is more than about8.2. A solution containing 100% of the di-sodium salt has pH of greaterthan about 11.5 as per speciation plot (FIG. 1). The high pH isunsuitable for dosing to human as a solution. pH adjustment from about7.2 to about 7.4 with mineral acid introduces additional salt, forexample, sodium chloride into the formulation.

The crystalline forms of the mono-sodium salt are ideal candidates toreplace the di-sodium salt in the preparation of different formulations.Administration of the novel crystalline salts of this invention asdescribed herein can be via any of the accepted modes of administrationfor systemically active therapeutic medicaments. These methods includeoral, parenteral and otherwise systemic, aerosol or topical forms.

Depending on the intended mode of administration, the compositions usedmay be in the form of solid, semi-solid or liquid dosage forms, such as,for example, tablets, sublingual tablets, suppositories, pills,capsules, powders, liquids, aerosols, suspensions, or the like,preferably in unit dosage forms suitable for single administration ofprecise dosages. The compositions will include at least one conventionalpharmaceutical carrier or excipient and crystalline mono-sodiumD-isoglutamyl-D-tryptophan and, in addition, may include other medicinalagents, pharmaceutical agents, carriers, adjuvants, etc.

For solid compositions, conventional non-toxic solid carriers includes,for example, pharmaceutical grades of mannitol, lactose, starch,magnesium stearate, sodium saccharin, talcum, cellulose, glucose,sucrose, magnesium carbonate, and the like may be used. The activecompound as defined above may be formulated as suppositories using, forexample, polyalkylene glycols, propylene glycol, as the carrier. Liquidpharmaceutically administerable compositions can, for example, beprepared by dissolving, dispersing, etc., an active compound as definedabove and optional pharmaceutical adjuvants in a carrier, such as, forexample, water, saline, aqueous dextrose, glycerol, ethanol, and thelike, to thereby form a solution or suspension. If desired, thepharmaceutical composition to be administered may also contain minoramounts of nontoxic auxiliary substances such as wetting or emulsifyingagents, pH buffering agents and the like, for example, sodium acetate,sorbitan monolaurate, triethanolamine sodium acetate, triethanolamineoleate, etc. Actual methods of preparing such dosage forms are known, orwill be apparent, to those skilled in this art; for example, seeRemington: The Science and Practice of Pharmacy, 21^(st) Edition, 2006,Part 5, Pharmaceutical Manufacturing, Chapters 37, 39, 41-47 and 50, pp.702-719, 745-775, 802-938, and 1000-1017 (formerly known as Remington'sPharmaceutical Sciences), David B. Troy (Ed.), Lipincott Williams &Wilkins, Baltimore, Md. The composition or formulation to beadministered will, in any event, contain a quantity of the activecompound(s) in an amount effective to alleviate the symptoms of thesubject being treated.

Parenteral administration is generally characterized by injection,either subcutaneously, intramuscularly or intravenously. Injectables canbe prepared in conventional forms, either as liquid solutions orsuspensions, solid forms suitable for solution or suspension in liquidprior to injection, or as emulsions. Suitable excipients are, forexample, water, saline, dextrose, glycerol, ethanol or the like. Inaddition, if desired, the pharmaceutical compositions to be administeredmay also contain minor amounts of non-toxic auxiliary substances such aswetting or emulsifying agents, pH buffering agents and the like, such asfor example, sodium acetate, sorbitan monolaurate, triethanolamineoleate, etc.

For the mono-sodium salt of D-isoglutamyl-D-tryptophan, either oral ornasal (bronchial) administration is preferred, depending on the natureof the disorder being treated.

For oral administration, a pharmaceutically acceptable non-toxiccomposition is formed by the incorporation of any of the normallyemployed excipients, such as, for example pharmaceutical grades ofmannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum,cellulose, glucose, sucrose, magnesium, carbonate, and the like.

Such compositions take the form of solutions, suspensions, tablets,pills, capsules, powders, sustained release formulations and the like.Such compositions may contain from about 1% to about 95% activeingredient, preferably from about 25% to about 70%.

Oral and nasal administration to the lungs can also be effected byaerosol delivery forms. For aerosol administration, the activeingredient is preferably supplied in finely divided form along with asurfactant and a propellant. Typical percentages of active ingredientsare from about 0.01 to about 20% by weight, preferably from about 0.04to about 1.0%.

Surfactants must, of course, be non-toxic, and preferably soluble in thepropellant. Representative of such agents are the esters or partialesters of fatty acids containing from 6 to 22 carbon atoms, such ascaproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic,olestearic and oleic acids with an aliphatic polyhydric alcohol or itscyclic anhydride such as, for example, ethylene glycol, glycerol,erythritol, arabitol, mannitol, sorbitol, the hexitol anhydrides derivedfrom sorbitol (the sorbitan esters sold under the tradename SPANS®) andthe polyoxyethylene and polyoxypropylene derivatives of these esters.Mixed esters, such as mixed or natural glycerides may be employed. Thepreferred surface-active agents are the oleates or sorbitan, e.g., thosesold under the tradenames ARLACEL® C (Sorbitan sesquioleate), SPAN® 80(sorbitan monooleate) and SPAN® 85 (sorbitan trioleate). The surfactantmay constitute from about 0.1% to about 20% by weight of thecomposition, preferably from about 0.25% to about 5%.

The balance of the composition is ordinarily propellant. Liquefiedpropellants are typically gases at ambient conditions, and are condensedunder pressure. Among suitable liquefied propellants are the loweralkanes containing up to five carbons, such as butane and propane; andpreferably fluorinated or fluorochlorinated alkanes, such as are soldunder the tradename FREON®. Mixtures of the above may also be employed.

In producing the aerosol, a container equipped with a suitable valve isfilled with the appropriate propellant, containing the finely dividedactive ingredient and surfactant. The ingredients are thus maintained atan elevated pressure until released by action of the valve.

For topical administration, these compositions comprise an effectiveamount of a compound of this class in admixture with a pharmaceuticallyacceptable non-toxic carrier. A suitable range of composition would befrom about 0.1% to about 10% active ingredient, and the balance carrier,preferably from about 1% to about 2% active ingredient. Theconcentration of active ingredient in pharmaceutical compositionssuitable for topical application will vary depending upon the particularactivity of the compound used in conjunction with the condition andsubject to be treated. Suitable carriers or medicament vehicles fortopical application of these compounds include creams, ointments,lotions, emulsions, solutions and the like.

For example, a suitable ointment for topical application of compounds ofthe present invention contains about 15 to about 45 percent of asaturated fatty alcohol having 16 to 24 carbon atoms such as cetylalcohol, stearyl alcohol, behenyl alcohol, and the like and about 45 toabout 85 wt. percent of a glycol solvent such as propylene glycol,polyethylene glycol, dipropylene glycol, and mixtures thereof. Theointment can also contain from about 0 to about 15 wt. percent of aplasticizer such as polyethylene glycol, 1,2,6-hexanetriol, sorbitol,glycerol, and the like; from about 0 to about 15 wt. percent of acoupling agent such as a saturated fatty acid having from 16 to 24carbon atoms, e.g., stearic acid, palmitic acid, behenic acid, a fattyacid amide e.g., oleamide, palmitamide, stearamide, behenamide and anester of a fatty acid having from 16 to 24 carbon atoms such as sorbitolmonostearate, polyethylene glycol monostearate, polypropylene glycol orthe corresponding mono-ester of other fatty acids such as oleic acid andpalmitic acid; and from about 0 to about 20 wt. percent of a penetrantsuch as dimethyl sulfoxide or dimethylacetamide.

A therapeutically active amount of the crystalline mono-sodium salt ofD-isoglutamyl-D-tryptophan may vary according to factors such as diseasestate, age, sex, and weight of the individual. Dosage regime may bealtered to provide the optimum therapeutic response. Generally, thedaily regimen should be in the range of from about 1 to about 200 mg ofpeptide.

The following are examples of representative formulations and in no wayrestrict the scope of in the preparation of different pharmaceuticalcompositions.

Ingredients Quantity per tablet mgs Active ingredient 25 lactose,spray-dried 20 Corn starch 153 magnesium stearate 2 The aboveingredients are thoroughly mixed and pressed into single scored tablets.

Ingredients Quantity per tablet mgs Active ingredient 100 lactose,spray-dried 148 magnesium stearate 2 The above ingredients are mixed andintroduced into a hard-shell gelatin capsule.

Ingredients Quantity per tablet mgs Active ingredient 200 lactose 145cornstarch 50 magnesium stearate 5 The above ingredients are mixedintimately and pressed into single scored tablets.

Ingredients Quantity per tablet mgs Active ingredient 108 lactose 15cornstarch 25 magnesium stearate 2 The above ingredients are mixed andintroduced into a hard-shell gelatin capsule.

Ingredients Quantity per tablet mgs Active ingredient 150 lactose 92 Theabove ingredients are mixed and introduced into a hard-shell gelatincapsule.

An injectable preparation buffered to a pH of 7 is prepared having thefollowing composition:

Ingredients Active ingredient 0.2 g KH₂PO₄   2 ml KOH (1N) q.s. to pH 7Water (distilled, sterile) q.s. to 20 ml

An injectable preparation buffered to a pH of 7 is prepared having thefollowing composition:

Ingredients Active ingredient 0.01 g Water (distilled, sterile) q.s. to1 ml NaOH (0.2N) q.s. to pH 7

An oral suspension is prepared having the following composition:

Ingredients Active ingredient 0.1 g fumaric acid 0.5 g methyl paraben2.0 g granulated sugar 0.1 g sorbitol (70% solution) 25.5 g Veegum K(Vanderbilt Co.) 12.85 g flavoring 1.0 g colorings 0.035 ml distilledwater q.s. to 100 ml

Topical Formulation

Ingredients Grams Active compound 0.2-2 Span 60 2 Tween 60 2 Mineral oil5 Petrolatum 10 Methyl paraben 0.15 Propyl paraben 0.05 BHA (butylatedhydroxy anisole) 0.01 distilled water q.s. 100 ml

All of the above ingredients, except water, are combined and heated to45 degree C. with stirring. A sufficient quantity of water at 45 degreeC. is then added with vigorous stirring to emulsify the ingredients, andwater then added q.s. 100 g.

Further details of the preferred embodiments of the present inventionare illustrated in the following examples which are understood to benon-limiting with respect to the appended claims.

EXAMPLES Example 1 Preparation of Crystal Modification 1 (PolymorphicForm F) of the Mono-Sodium Salt of D-Isoglutamyl-D-Tryptophan (1:1)Method A: From the Mono-Ammonium Salt of D-Isoqiutamyl-D-Tryptophan(1:1) and Sodium Hydroxide.

A solution of H-D-iGlu-D-Trp-OH, mono-ammonium salt (1:1), (496 mg, 1.34mmol) and 1N sodium hydroxide (1.4 mL, 1.40 mmol) in water (15 mL) wasstirred at room temperature for 30 min. The reaction mixture wasevaporated under reduced pressure to about 1-2 mL of solvent. Aftercooling down to room temperature, isopropanol (30 mL) was added until asolid precipitated out. The resulting suspension was stirred overnightat room temperature, after which the solid was collected by suctionfiltration. The solid was washed with isopropanol (2×40 mL) and thendried overnight in an oven at 44° C. An off white crystalline solid wasobtained (462 mg, 97% yield). This material is named crystalmodification 1 (polymorphic form F) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan (1:1).

The water content of this material was 3.4% as determined byKarl-Fischer test.

MS (m/z): 356.0 [M]⁺, 334.1 [C₁₆H₂₀N₃O₅]⁺, 187.9 (100%).

The XRPD pattern of this material is shown in FIG. 2. This XRPD patternmay also be expressed in terms of inter-planar distances d, Bragg'sangle 2 theta, and relative intensity (expressed as a percentage withrespect to the most intense ray) as follows:

2 Theta D-spacing Relative Intensity (°) (Angstrom) (%) 9.23 9.573 29.91 8.917 41.3 12.41 7.126 37.6 13.76 6.43 0.8 14.87 5.954 35.8 15.755.622 7.6 17.88 4.957 5.5 18.78 4.721 58.9 19.57 4.532 30.9 19.84 4.47128.1 20.31 4.368 2.9 21.32 4.165 53.5 21.55 4.12 30.3 22.95 3.873 67.423.45 3.79 24.5 24.34 3.654 19.4 24.96 3.565 85.2 27.49 3.242 100 27.943.19 23.3 29.27 3.049 19.1 30.07 2.97 27.2 30.43 2.935 15.2 31.29 2.85639.9 32.25 2.774 13 34.07 2.629 19.3 34.94 2.566 7.8 35.53 2.525 5 36.082.487 8.4 37.21 2.414 15.5 38.17 2.356 9.1

The powdered samples were prepared by a normal front packing techniqueand run on a D8 Discovery Diffractometer system with Cu-kα sourceoperating at 45 kV/45 mA. The system is equipped with 2D—proportionalarea detector (GADDS). The experimental data were collected on twoframes at 600 s exposure of each one that covered the range of 3°-35°(2-theta). The obtained 2D diffraction images were then integrated inorder to obtain standard, I vs. 2-theta, diffraction patterns. The datawere processed by various Bruker AXS data processing software including:EVA™ 8.0 and TOPAS™ v. 2.1 (for profile fitting analysis andapplications, when necessary). All of the XRPD patterns included hereinwere determined using the technique, instrument and settings asdescribed above.

The FT-IR (KBr) spectrum of this material is shown in FIG. 5.

Method B: From D-isoglutamyl-D-tryptophan and sodium hydroxide.

In a 100 mL round bottom flask equipped with a magnetic stir bar wasplaced 2.91 mL of sodium hydroxide (1.000 N, 2.91 mmoL) and 2.91 mL ofdeionized water. The solution was cooled to 0° C. using an ice waterbath, and solid H-D-iGlu-D-Trp-OH (1.00 g, 3.00 mmol) was added all atonce. Another 3 mL of deionized water was added, and the resultingsolution was stirred for another 15 min. The pH of the solution wasabout 5.5 to about 6.0. The pH was adjusted to about 6.5 with theaddition of 40 μM of a 0.500N solution of NaOH solution. The mixture wasfiltered to remove any solid particulates, and the filtrate was thenconcentrated in vacuo to about 0.5 mL of solution at a bath temperatureof 30° C. The residue was diluted with 0.6 mL of deionized water andisopropanol (10 mL) was added with vigorous stirring and a solidprecipitated out. The mixture was sonicated for a few min. Then, another30 mL of isopropanol was added. After stirring for 90 min, the mixturewas divided into two parts (A and B).

A. The Part A mixture was filtered and the solid was washed withisopropanol (2×10 mL). The solid was air dried for about 1 h, and thendried overnight under vacuum in an oven at 40° C. The XRPD pattern andIR (KBr) spectrum of this part A material are similar to the polymorphicform F shown in FIG. 2 and FIG. 5, respectively as described in Method Aabove.

B. The Part B mixture was stirred overnight. The mixture was thenfiltered, and the solid was washed with 2×10 mL of isopropanol, airdried for about 15 min, then dried overnight under vacuum at 40° C. TheXRPD pattern and IR (KBr) spectrum of this part B material are similarto the polymorphic form F shown in FIG. 2 and FIG. 5, respectively asdescribed in Method A above.

Example 2 Preparation of Crystal Modification 2 (Polymorphic Form I) ofthe Mono-Sodium Salt of D-Isoglutamyl-D-Tryptophan (1:1)

In a 100 mL round bottom flask equipped with a magnetic stir bar wasplaced 2.97 mL of sodium hydroxide (1.000 N, 2.97 mmoL) and 3.0 mL ofdeionized water. The solution was cooled to 0° C. using an ice waterbath, and solid H-D-iGlu-D-Trp-OH (1.00 g, 3.00 mmol) was added all atonce, to give a clear slightly pinkish solution. The pH of the solutionwas about 7.0. The mixture was filtered to remove any solidparticulates, and the filtrate was then concentrated in vacuo to give anoil. The residue was diluted with 0.6 mL of deionized water, andisopropanol (40 mL) was added with vigorous stirring and a solidprecipitated out. After stirring for 1 h, the mixture was then filtered,and the solid was washed with 2×15 mL of isopropanol, air dried forabout 15 min, then dried overnight under vacuum at 36° C. A whitecrystalline solid was obtained (1.00 g, 94% yield). This material isnamed crystal modification 2 (polymorphic form I) of the mono-sodiumsalt of D-isoglutamyl-D-tryptophan (1:1).

This material had an HPLC purity (peak area percent) of 98.5%. HPLCmethod; Column: XTerra MS C18; 5 μm, 4.6×250 mm; Mobile phase: A=theaqueous phase: 4 mM Tris, 2 mM EDTA, pH 7.4; B=the organic phase: CH₃CN;gradient: B %: 0 min. 5%, 15 min. 55%, 30 min. 55%, 32 min. 5%, 35 min.5%; Flow rate: 1 mL/min; injection volume: 5 μL; λ: 222, 254, 280, 450nm; retention time of the product: 6.39 min.

The water content of this material was 6.0% as determined byKarl-Fischer test.

UV (water, c=22.4 μM, λ_(max) nm): 221 (ε30528), 280 (ε4958).

MS (m/z): 356.0 [M]⁺, 334.2 [C₁₆H₂₀N₃O₅]⁺, 187.9 (100%).

The XRPD pattern of this material is shown in FIG. 3. The XRPD patternmay also be expressed in terms of inter-planar distances d, Bragg'sangle 2 theta, and relative intensity (expressed as a percentage withrespect to the most intense ray) as follows:

2 Theta D-spacing Relative Intensity (°) (Angstrom) (%) 9.65 9.161 5.310.41 8.492 23.7 11.2 7.897 40.4 11.71 7.549 4.5 13.45 6.58 90.2 13.936.351 15.9 14.44 6.128 3.7 15.61 5.672 32.4 17.01 5.207 9.9 18.18 4.87611.7 18.65 4.755 47.8 20.02 4.432 59.2 20.85 4.257 35.9 21.39 4.15 24.121.73 4.086 27.3 22.52 3.945 100 23.27 3.819 13.7 24.3 3.66 32.4 25.843.445 69.5 26.82 3.322 82.5 28.49 3.13 30.1 30.18 2.959 58.8 30.76 2.90486.9 31.49 2.839 35.3 33.03 2.71 8.7 34.55 2.594 17.8 34.97 2.564 43.435.74 2.51 8.5 37.25 2.412 28.1 37.71 2.383 28.5 38.79 2.319 16.9

The FT-IR (KBr) spectrum of this material is shown in FIG. 6.

This material was prepared in a similar manner as described below:

De-ionized water (18 mL) and 1N NaOH solution (18.0 mL, 18 mmol) werecombined in a 250 mL round bottom flask and cooled to 0° C. SolidH-D-iGlu-D-Trp-OH (6.0 g, 18 mmol) was added and slowly dissolved. After1 h, the solution had become a pale peach colour. A portion of thissolution (6 mL) was removed and evaporated in vacuo to an oil. The oilwas diluted with 0.6 mL of de-ionized water and IPA (40 mL) was addeddropwise. The mixture was stirred vigorously for 1 h and then filtered.The solid was air dried and then dried overnight in a vacuum oven toafford 450 mg of the compound as a white solid, mp: 186.9-189.2° C. TheXRPD and IR spectra of this material were similar to those provided inFIG. 3 and FIG. 6, respectively as described above.

Example 3 Preparation of Crystal Modification 3 (Polymorphic Form X) ofthe Mono-Sodium Salt of D-Isoglutamyl-D-Tryptophan (1:1)

Method A: Solid mono-sodium salt of D-isoglutamyl-D-tryptophan (800 mg)prepared as described in Example 1, Method B above, was suspended inmethanol (10 mL). The mixture was slightly heated to dissolve the solid.The solution was filtered twice through a sintered glass funnel andcollected into a 100 mL round bottom flask. The flask was equipped witha stir bar and IPA (4 mL) was added slowly until a solid formed. Thesuspension was stirred for 4 h and then filtered. The solid was washedwith IPA (3×10 mL). The solid was air-dried (solid became a pale peachcolour) and then dried overnight in a vacuum oven. A white crystallinesolid was obtained (480 mg, 60% yield), mp: 182.3-186.1° C. Thismaterial is named crystal modification 3 (polymorphic form X) of themono-sodium salt of D-isoglutamyl-D-tryptophan (1:1).

The XRPD pattern of this material is shown in FIG. 4. The XRPD patternmay also be expressed in terms of inter-planar distances d, Bragg'sangle 2 theta, and relative intensity (expressed as a percentage withrespect to the most intense ray) as follows:

2 Theta D-spacing Relative Intensity (°) (Angstrom) (%) 9.187 9.618 25.411.058 7.995 2.3 11.713 7.549 18.7 12.239 7.226 34.2 13.785 6.419 23.514.806 5.978 13 15.763 5.618 5 17.126 5.173 29.3 17.693 5.009 8.4 18.2684.852 48.2 18.562 4.776 28.2 19.261 4.604 14.3 20.033 4.429 14.5 20.634.302 17.2 21.006 4.226 12 21.778 4.078 2.4 22.268 3.989 100 23.0543.855 6.4 23.361 3.805 7.4 23.851 3.728 1.8 24.626 3.612 14.9 24.9813.562 14.7 25.507 3.489 11.1 26.257 3.391 34.3 26.963 3.304 11.1 27.3293.261 20.6 27.807 3.206 35 28.243 3.157 25.6 28.975 3.079 1.1 29.2643.049 2.3 29.687 3.007 9.5 30.409 2.937 20.9 30.798 2.901 6.1 31.1932.865 6.9 31.724 2.818 24.7 32.505 2.752 8 32.985 2.713 12.1 33.6452.662 26.5 34.249 2.616 15.2 34.587 2.591 8.6 35.048 2.558 4.6 35.412.533 3.3 35.933 2.497 15.3 36.833 2.438 8 37.276 2.41 10.8 37.937 2.3712.7 38.467 2.338 14.7 39 2.308 2.6

The water content of this material was 9.3% as determined byKarl-Fischer test.

MS (m/z): 356.0 [M]⁺, 334.2 [C₁₆H₂₀N₃O₅]⁺, 187.9 (100%).

The FT-IR (KBr) spectrum is provided in FIG. 7.

Method B: De-ionized water (6 mL) and 1N NaOH solution (6.0 mL, 6 mmol)were mixed in a 100 mL round bottom flask and cooled to 0° C. SolidH-D-iGlu-D-Trp-OH (2.0 g, 6 mmol) was added, and the mixture wassonicated for about 2 min to dissolve all of the solid. The pH of thesolution was about 6.0. A portion of this solution (6 mL) was removedand filtered to remove any solid particulates. The filtrate wasevaporated in vacuo to give a solid (1.02 g). A portion of the solid(0.5 g) was dissolved in de-ionized water (10 mL) to give a clearcolorless solution. Volatiles were removed in vacuo using a rotaryevaporator with ice-water for condenser cooling and at a bathtemperature of 30° C. over a period of 6 h to give a solid. The XRPDpattern and IR spectrum of this material were similar to those providedin FIG. 4 and FIG. 7, respectively as described in Method A above.

Example 4 Preparation of Mixture of Crystal Modification 1 (PolymorphicForm F) and Crystal Modification 3 (Polymorphic Form X) of theMono-Sodium Salt of D-Isoglutamyl-D-Tryptophan (1:1)

In a 50 mL round bottom flask equipped with a magnetic stir bar wasplaced 3.0 mL of NaOH (1.0 M, 3 mmol) and 3 mL of distilled water. Thesolution was cooled to 0° C. using an ice water bath, and solidH-D-iGlu-D-Trp-OH (1.00 g, 3.0 mmol) was added to give a clear pinksolution. The solution was allowed to stir at ice-cold temperature for 1h and then warm to room temperature. The solution was filtered and thenconcentrated to about 1 mL of solvent. IPA (38 mL) was added until asolid precipitate formed. The solution was stirred vigorously for 1 h.Half of this solution was filtered and washed with 2×15 mL of IPA. Thesolid was air dried, and then dried overnight in a vacuum oven at 35° C.to yield 379 mg of a white crystalline solid. This material is a mixtureof crystal modification 1 (polymorphic form F) and crystal modification3 (polymorphic form X) of the sodium salt of D-isoglutamyl-D-tryptophan(1:1). The XRPD pattern of this material is provided in FIG. 9.

A portion of the solid obtained as described above (50 mg) was suspendedand stirred in 3 mL of ethyl acetate at room temperature. After 2.5 h,the solution was filtered, the solid was air-dried and then driedovernight in a vacuum oven to afford 38 mg (78% yield) of a whitecrystalline solid. Analysis of the XRPD pattern indicated that thismaterial is essentially crystal modification 1 (polymorphic form F) ofthe mono-sodium salt of D-isoglutamyl-D-tryptophan (1:1) as described inExample 1 above, the XRPD pattern of which is provided in FIG. 2.

The XRPD patterns for crystal modifications 1, 2, and 3 of themono-sodium salt of D-isoglutamyl-D-tryptophan described above areprovided in FIGS. 2, 3 and 4, respectively. It will be understood bythose skilled in the art that the 2-theta values in the XRPD patternsfor crystal modifications 1, 2, and 3 of the mono-sodium salt ofD-isoglutamyl-D-tryptophan may vary slightly from one machine to anotherand/or from one sample to another, and so the values quoted are not tobe construed as absolute. 2-theta values should typically bereproducible to about ±0.2 degrees, preferably to about ±0.1 degrees. Itwill also be understood by those skilled in the art that the relativeintensities of the peaks in the XRPD patterns for crystal modifications1, 2 and 3 of the mono-sodium salt of D-isoglutamyl-D-tryptophan mayvary considerably from one machine to another and/or from one sample toanother, and so the values quoted are not to be construed as absolute.

Although preferred embodiments of the present invention have beendescribed herein, it will be understood by those skilled in the art thatvariations may be made thereto without departing from the spirit of theinvention or the scope of the appended claims.

1. A crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan, whereinthe crystalline material is crystal modification 1 (polymorphic form F).2. The crystal modification 1 (polymorphic form F) of the mono sodiumsalt of D-isoglutamyl-D-tryptophan of claim 1, having a XRPD pattern asshown in FIG.
 2. 3. The crystal modification 1 (polymorphic form F) ofthe mono sodium salt of D-isoglutamyl-D-tryptophan of claim 1, having anXRPD pattern comprising peaks, in terms of 2θ, at: 9.23±0.20, 9.91±0.20,12.41±0.20, 13.76±0.20, 14.87±0.20, 15.75±0.20, 17.88±0.20, 18.78±0.20,19.57±0.20, 19.84±0.20, 20.31±0.20, 21.32±0.20, 21.55±0.20, 22.95±0.20,23.45±0.20, 24.34±0.20, 24.96±0.20, 27.49±0.20, 27.94±0.20, 29.27±0.20,30.07±0.20, 30.43±0.20, 31.29±0.20, 32.25±0.20, 34.07±0.20, 34.94±0.20,35.53±0.20, 36.08±0.20, 37.21±0.20, 38.17±0.20, 39.19±0.20, and9.23±0.20.
 4. The crystal modification 1 (polymorphic form F) of themono sodium salt of D-isoglutamyl-D-tryptophan of claim 1, having anXRPD pattern comprising peaks, in terms of 2θ, at: 9.23±0.10, 9.91±0.10,12.41±0.10, 13.76±0.10, 14.87±0.10, 15.75±0.10, 17.88±0.10, 18.78±0.10,19.57±0.10, 19.84±0.10, 20.31±0.10, 21.32±0.10, 21.55±0.10, 22.95±0.10,23.45±0.10, 24.34±0.10, 24.96±0.10, 27.49±0.10, 27.94±0.10, 29.27±0.10,30.07±0.10, 30.43±0.10, 31.29±0.10, 32.25±0.10, 34.07±0.10, 34.94±0.10,35.53±0.10, 36.08±0.10, 37.21±0.10, 38.17±0.10, 39.19±0.10, and9.23±0.10.
 5. The crystal modification 1 (polymorphic form F) of themono sodium salt of D-isoglutamyl-D-tryptophan of claim 1, having anXRPD pattern measured using a diffractometer (copper anti-cathode) andexpressed in terms of inter-planar distances d, Bragg's angle 2 theta,and relative intensity (expressed as a percentage with respect to themost intense ray) as follows: 2-Theta D-spacing Relative Intensity (°)(Angstrom) (%) 9.23 9.573 2 9.91 8.917 41.3 12.41 7.126 37.6 13.76 6.430.8 14.87 5.954 35.8 15.75 5.622 7.6 17.88 4.957 5.5 18.78 4.721 58.919.57 4.532 30.9 19.84 4.471 28.1 20.31 4.368 2.9 21.32 4.165 53.5 21.554.12 30.3 22.95 3.873 67.4 23.45 3.79 24.5 24.34 3.654 19.4 24.96 3.56585.2 27.49 3.242 100 27.94 3.19 23.3 29.27 3.049 19.1 30.07 2.97 27.230.43 2.935 15.2 31.29 2.856 39.9 32.25 2.774 13 34.07 2.629 19.3 34.942.566 7.8 35.53 2.525 5 36.08 2.487 8.4 37.21 2.414 15.5 38.17 2.356 9.139.19 2.297 3.1


6. The crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan ofclaim 1, wherein the crystalline material is a mixture of the crystalmodification 1 (polymorphic form F) and the crystal modification 2(polymorphic form I) of the mono sodium salt ofD-isoglutamyl-D-tryptophan.
 7. The pharmaceutical composition comprisingthe crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan of anyone of claims 1 to 5, and at least one pharmaceutically acceptablecarrier.
 8. The pharmaceutical composition of claim 7, wherein thecrystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixtureof crystal modification 1 (polymorphic form F) and crystal modification2 (polymorphic form I) of the mono-sodium salt ofD-isoglutamyl-D-tryptophan.
 9. The pharmaceutical composition of claim7, wherein the crystalline mono-sodium salt ofD-isoglutamyl-D-tryptophan is a mixture of crystal modification 1(polymorphic form F) and crystal modification 3 (polymorphic form X) ofthe mono-sodium salt of D-isoglutamyl-D-tryptophan.